TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21219433
Drug: 50% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% dose of rapid-acting insulin (mean 3.7±0.1 units)
Study: 21219433
Drug: 25% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% dose of rapid-acting insulin (mean 1.8±0.1 units)
Study: 19968379
Drug: MoodGYM online
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoodGYM online cognitive behavioral therapy program
Study: 17010221
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg G115
Study: 17010221
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg G115
Study: 17010221
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg ginseng and 30 mg saccharin)
Study: 17010221
Drug: Ginseng (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (200 mg ginseng and 30 mg saccharin)
Study: 17010221
Drug: Placebo-glucose (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-glucose (0 mg ginseng and 25 g oral glucose)
Study: 17010221
Drug: Ginseng-glucose (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng-glucose (200 mg ginseng and 25 g oral glucose)
Study: 15463873
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate (Immunocal, 10 g twice a day)
Study: 3549844
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin supplementation
Study: 30269642
Drug: Phentermine 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 45 mg
Study: 30269642
Drug: Phentermine 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 90 mg
Study: 20157323
Drug: Taranabant 4
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 4 mg
Study: 22722508
Drug: Taranabant 20
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 20 mg
Study: 22722508
Drug: Taranabant (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant (various doses)
Study: 22722508
Drug: Phentermine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine (various doses)
Study: 19900726
Drug: NT-pro-BNP ≥180
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-pro-BNP ≥180 pg/ml
Study: 18272335
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (300 mg/d)
Study: 14595277
Drug: Tongue suspension
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue suspension
Study: 8683249
Drug: GM‐CSF 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF 24 hours before and during chemotherapy (arm +/‐)
Study: 8683249
Drug: GM‐CSF after
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF after chemotherapy until day 28 or recovery of PMNs (arm ‐/+)
Study: 8683249
Drug: GM‐CSF before,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF before, during, and after chemotherapy (arm +/+)
Study: 1906864
Drug: Twice-daily amikacin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily amikacin (7.5 mg/kg bd) regimen (group A)
Study: 1906864
Drug: Once-daily amikacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily amikacin (15 mg/kg) schedule (group B)
Study: 6802391
Drug: Regimen using
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen using simple dietary instructions and laxatives
Study: 29157960
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) inactivated seasonal influenza vaccine
Study: 29157960
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) inactivated seasonal influenza vaccine
Study: 26002596
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) plus graded exercise therapy
Study: 21476931
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release (GXR) 1, 2, and 3 mg/day
Study: 19066370
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 microg/d from L-selenomethionine)
Study: 17606443
Drug: Double, intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double, intensive treatment (two cycles of non‐myeloablative intermediate‐dose melphalan 70 mg/m2 followed by cyclophosphamide 120 mg/kg iv plus total body irradiation 9 Gy and autologous stem cell transplantation)
Study: 17606443
Drug: Single non‐myeloablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single non‐myeloablative treatment (two cycles of non‐myeloablative intermediate‐dose melphalan 70 mg/m2)
Study: 17606443
Drug: Double, intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double, intensive treatment
Study: 17606443
Drug: Single non‐myeloablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single non‐myeloablative treatment
Study: 11393219
Drug: Buserelin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (40 microg in 4 doses i.v. at 12 h intervals)
Study: 11393219
Drug: Buserelin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (40 microg in 4 doses i.v.)
Study: 11393219
Drug: Buserelin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (4 doses of 20 microg i.v.)
Study: 11393219
Drug: Buserelin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (3 doses of 13.3 microg at 6 h interval)
Study: 3545418
Drug: 14-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-valent pneumococcal vaccine
Study: 23868419
Drug: HIV care
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV care and treatment services
Study: 21948457
Drug: Hydrophilic matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic matrix based modified release formulations
Study: 21948457
Drug: Predictions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictions of in vivo drug release
Study: 15918525
Drug: Myung In
Normalized name: Mung bean
DrugBank: Mung bean (DB10830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myung In haloperidol (test drug)
Study: 15918525
Drug: Peridol (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peridol (reference drug)
Study: 10367550
Drug: Naltrexone tablet
Normalized name: naltrexone Oral Tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone tablet (50 mg) plus placebo skin patch
Study: 10367550
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus nicotine skin patch (21 mg/24 h)
Study: 10367550
Drug: Naltrexone tablet
Normalized name: naltrexone Oral Tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone tablet plus nicotine skin patch
Study: 10367550
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus placebo skin patch
Study: 8896495
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine trial participation willingness
Study: 1854025
Drug: 60 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 micrograms/kg of oxycodone
Study: 6340820
Drug: Levamisole 150
Normalized name: levamisole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 150 mg for three days, two weekly
Study: 24810181
Drug: Linifanib administered
Normalized name: Linifanib
DrugBank: Linifanib (DB06080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib administered with food
Study: 24810181
Drug: Linifanib administered
Normalized name: Linifanib
DrugBank: Linifanib (DB06080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linifanib administered in the evening after a 2-h fast
Study: 15907955
Drug: 2.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/kg of 100 proof (50% absolute ethanol) vodka
Study: 10654204
Drug: Salbutamol (S),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (S), 100 micrograms/puff, delivered with a metered-dose inhaler (MDI) and a spacer at a tidal volume (VT) of 8 ml/kg (normal VT)
Study: 10654204
Drug: Salbutamol (S),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (S), 100 micrograms/puff, delivered with a metered-dose inhaler (MDI) and a spacer at a tidal volume (VT) of 12 ml/kg (high VT)
Study: 9456189
Drug: Epirubicin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin treatment
Study: 6351891
Drug: 10 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg/day of slow release theophylline
Study: 28409851
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxygen and eszopiclone
Study: 23645340
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg) 1 hour before surgery and ramosetron immediately after surgery (Dexa‐Ra group, n = 135)
Study: 31515397
Drug: Biologic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapies
Study: 12707578
Drug: Studies of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Studies of biologic agents
Study: 8698440
Drug: cilazapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (5 mg twice daily)
Study: 6089862
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (22.5 g/l)
Study: 6089862
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (36 g/l)
Study: 7856453
Drug: Cervical electrostimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical electrostimulation (30 minutes, twice a week for a total of 10 sessions, 18 msec duration, 100 Hz frequency)
Study: 2510261
Drug: Rioprostil 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rioprostil 600 micrograms/daily
Study: 2510261
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg/daily
Study: 21234555
Drug: Desmopressin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (40 mg, nasal spray)
Study: 11251523
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg, intramuscularly)
Study: 19832818
Drug: Lornoxicam (LNX)
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (LNX) 8‐24 mg/day
Study: 19832818
Drug: Diclofenac 100‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100‐150 mg/day
Study: 15746053
Drug: Oral irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irinotecan at 80 mg/m(2)/day
Study: 15746053
Drug: Oral irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irinotecan at 70 mg/m(2)/day
Study: 15746053
Drug: Oral irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irinotecan (both dosages)
Study: 15746053
Drug: Food effect
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food effect on oral irinotecan
Study: 15746053
Drug: Oral irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral irinotecan
Study: 9678288
Drug: Irbesartan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (1 to 900 mg orally)
Study: 7986392
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly injections of GH (group 1)
Study: 7986392
Drug: Daily injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injections of GH (group 2)
Study: 7986392
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections (group 3)
Study: 28446804
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of amlodipine (10 mg) with irbesartan (100 mg)
Study: 28446804
Drug: Indapamide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (1 mg) with irbesartan (100 mg) and amlodipine (5 mg)
Study: 25204992
Drug: American cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: American cranberry (120 mg)
Study: 25204992
Drug: Routine prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine prophylactic therapy (control group)
Study: 16865033
Drug: Case management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management plus community referral for individual treatment
Study: 12872354
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus gemcitabine at a 30-minute standard infusion (Arm A)
Study: 12872354
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus gemcitabine at a fixed infusion rate of 10 mg/m2 per minute (Arm B)
Study: 7539185
Drug: Phytotherapeutic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytotherapeutic agents
Study: 2693073
Drug: Clonidine (0.225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.225 mg/day for the first week, increased to 0.450 mg/day for the second week)
Study: 359562
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin combined with sulfinpyrazone
Study: 30954969
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of csDMARDs
Study: 30954969
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of TNF inhibitors
Study: 30954969
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of csDMARDs and TNF inhibitors
Study: 21604206
Drug: Alcohol-based skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-based skin antiseptics (5 different solutions)
Study: 16780618
Drug: Oral analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics (paracetamol 1 g four times a day and ibuprofen 500 mg three times a day)
Study: 11169172
Drug: 24% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% NaCl solution
Study: 31482765
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug (ATD) therapy
Study: 31482765
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radioactive iodine (131I) therapy
Study: 31482765
Drug: Ablative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative treatment (surgery or 131I)
Study: 31482765
Drug: Normal thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal thyroid hormone status without thyroxine supplementation
Study: 24553426
Drug: rs1229984 G→A
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs1229984 G→A polymorphism
Study: 17706223
Drug: IL-10 concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 concentration >= 1.04 pg/mL
Study: 17706223
Drug: IL-10 concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 concentration < 1.04 pg/mL
Study: 10585065
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (mitomycin C 10 mg/m2, vinblastine 6 mg/m2, cisplatin 100 mg/m2)
Study: 6338164
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone phosphate (100 mg administered within 6 hours of the accident)
Study: 28119041
Drug: Capecitabine monotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine monotherapy (X)
Study: 17483009
Drug: Applephenon (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applephenon (1200 mg/d)
Study: 17483009
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1000 mg/d)
Study: 11593916
Drug: Naproxen 10
Normalized name: naproxen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 10 mg/kg BW bid for 2 weeks
Study: 11593916
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and paracetamol as needed
Study: 9589685
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day, orally for 8 weeks)
Study: 26658899
Drug: Citrulline malate
Normalized name: CITRULLINE MALATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline malate (CM) 8 g dextrose + 8 g CM
Study: 26658899
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 g dextrose)
Study: 22451347
Drug: Echinacea angustifolia
Normalized name: Echinacea Angustifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea angustifolia extract (20 mg, 2 tablets per day)
Study: 22451347
Drug: Echinacea angustifolia
Normalized name: Echinacea Angustifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea angustifolia extract (20 mg, 1 tablet per day)
Study: 22451347
Drug: Echinacea angustifolia
Normalized name: Echinacea Angustifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea angustifolia extract (1000 and 3000 mg/kg) in rats
Study: 22451347
Drug: Echinacea angustifolia
Normalized name: Echinacea Angustifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea angustifolia extract (various doses) in rats
Study: 17081623
Drug: Interferon-beta treatment
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta treatment
Study: 9489643
Drug: PBPC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PBPC infusion over 1 day
Study: 9489643
Drug: PBPC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PBPC infusion over 2 days
Study: 9489643
Drug: PBPC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PBPC infusion over 3 days
Study: 9489643
Drug: PBPC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PBPC infusion as a single infusion
Study: 9489643
Drug: PBPC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PBPC infusion over 1, 2 or 3 days
Study: 8165854
Drug: Four-dose schedule
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose schedule (40 micrograms each at 0, 1, 2, and 6 months)
Study: 8165854
Drug: Three-dose schedule
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose schedule (40 micrograms each at 0, 1, and 6 months)
Study: 8165854
Drug: Three-dose schedule
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose schedule (half the amount of vaccine) in healthy controls
Study: 8165854
Drug: Four-dose schedule
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose schedule
Study: 8165854
Drug: Three-dose schedule
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose schedule
Study: 8165854
Drug: Three-dose schedule
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose schedule in healthy controls
Study: 8165854
Drug: Four-dose and
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose and three-dose schedules
Study: 3073355
Drug: TISACID (Al-Mg-hydroxy-carbonate)
Normalized name: alpha hydroxy acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: TISACID (Al-Mg-hydroxy-carbonate)
Study: 3073355
Drug: TISACID (Al-Mg-hydroxy-carbonate)
Normalized name: alpha hydroxy acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: TISACID (Al-Mg-hydroxy-carbonate) with cimetidine
Study: 29637322
Drug: Early education
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early education treatment group
Study: 29637322
Drug: Intensive early
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive early educational treatment
Study: 22162542
Drug: Telaprevir 750
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 750 mg every 8 hours from day 8 through day 23
Study: 12222545
Drug: 30-gauge, 5/16-inch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-gauge, 5/16-inch insulin syringe
Study: 10520785
Drug: Adjunctive percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive percutaneous transluminal coronary angioplasty (PTCA) after DCA
Study: 10520785
Drug: Adjunctive PTCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive PTCA
Study: 7486603
Drug: 30-mg dose
Normalized name: pasireotide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg dose of nimodipine
Study: 7486603
Drug: 60-mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-mg dose of nimodipine
Study: 2138490
Drug: Mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mivacurium chloride (0.15 mg kg‐1) during nitrous oxide-fentanyl-thiopentone anaesthesia (BAL group)
Study: 2138490
Drug: Mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mivacurium chloride (0.15 mg kg‐1) during nitrous oxide-halothane anaesthesia (HAL group)
Study: 2138490
Drug: Mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mivacurium chloride (various doses)
Study: 7328681
Drug: Communication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communication therapy
Study: 30302786
Drug: Risdiplam (0.6-18.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risdiplam (0.6-18.0 mg, n=18)
Study: 28675594
Drug: Single-dose letermovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose letermovir (120, 240, 480, 720, and 960 mg)
Study: 28675594
Drug: Multiple-dose letermovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose letermovir (240 mg, once-daily)
Study: 24950277
Drug: Delayed varicosity
Normalized name: DIMETHICONE 30 mg in 1 mL TOPICAL CREAM [AnYi Beauty Varicose Veins Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed varicosity treatment